Trials / Completed
CompletedNCT00547144
Phase I/II Intratumoral DC Immunotherapy With Gemcitabine & XRT in Unresectable Pancreatic Cancer
A Phase I/II Trial of Intratumoral Dendritic Cell Immunotherapy in Combination With Gemcitabine and Stereotactic Radiosurgery in Unresectable Pancreatic Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- George Albert Fisher · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine the safety, feasibility and appropriate dendritic cell dose to vaccinate patients with pancreas cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gemcitabine | 1000 mg/m2 intravenoulsy once a week according to protocol schedule |
| PROCEDURE | Dendritic Cell Immunotherapy | The cells will be administered by intratumoral injection on 2 different days(at least 21 days apart) |
Timeline
- Start date
- 2005-10-01
- Primary completion
- 2008-04-01
- Completion
- 2008-04-01
- First posted
- 2007-10-22
- Last updated
- 2012-11-08
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00547144. Inclusion in this directory is not an endorsement.